- Geopolitical Strategist
United States, Intermediary
Change
The views expressed are those of the authors at the time of writing. Other teams may hold different views and make different investment decisions. The value of your investment may become worth more or less than at the time of original investment. While any third-party data used is considered reliable, its accuracy is not guaranteed. For professional, institutional, or accredited investors only.
In the latest episode of WellSaid, co-heads of biotech private investments I-hung Shih and Nilesh Kumar join host Thomas Mucha to explore today's private biotech market, highlighting the state of deal flow, valuations, and innovation.
Listen below or on Simplecast, Apple, and Spotify.
Key topics:
1:30 – The impact of scientific training on biotech investing
6:30 – The state of the private biotech market
9:30 – Groundbreaking innovations
12:15 – Secular trends in biotech investing
13:45 – Biotech’s valuation reset
16:15 – Regulation and drug pricing
19:15 – Wellington's broader health care perspectives
20:55 – The intersection of geopolitics and biotech innovation
23:30 – Collaborating with Wellington’s public health care team
26:15 – ESG and bioethics
Experts
- Head of Biotech Private Investments
Related insights
Showing
of
Insights Posts
Article
5 min
Venture capital outlook for 2026: 5 key trends
Continue reading
5 min
Article
2026-12-31
Article
7 min
Human capital management for private companies
Continue reading
7 min
Article
2026-11-30
URL References
Related Insights
Stay up to date with the latest market insights and our point of view.
Read next
Showing
of
Insights Posts
Article
5 min
Venture capital outlook for 2026: 5 key trends
We explore 2026's venture capital trends, highlighting IPO momentum, M&A acceleration, secondary market growth, public-private convergence, and the focus on quality investments.
5 min
Article
2026-12-31
Article
7 min
Human capital management for private companies
We discuss why effective people management is critical for private companies and outline four strategic focus areas that can help companies navigate evolving employee needs, regulatory changes, and investor expectations.
7 min
Article
2026-11-30
Article
10 min
Venture and growth equity: The future of private-market evergreen funds?
Investment Director Cara Hubbard highlights how the VC and growth equity landscapes are transforming, details the rising popularity of evergreen funds, and shares how these themes may converge to expand access to private markets.
10 min
Article
2026-10-31
Article
6 min
Understanding private equity performance
We dive deep on best practices for measuring and benchmarking private equity performance. In addition, we outline the J-curve and the impact of fund lifecycle on returns.
6 min
Article
2026-07-31
Article
17 min
Allocating to alternatives: A role-based guide for corporate DB plans
For corporate plan sponsors thinking about weaving hedge funds and private equity into their portfolios, we offer this brief guide to the potential benefits and key considerations when establishing an allocation, including liquidity stress testing.
17 min
Article
2027-06-30
Article
5 min
Venture capital mid-year outlook: Five key questions
Our venture capital team explores the state of the IPO market, M&A uncertainty, the growth of secondaries, and more.
5 min
Article
2026-06-30
Video
3 min
Innovation in late-stage private markets
Matt Witheiler, head of Late-stage Growth, explores innovation and hype in late-stage private markets, discussing AI and defense technology.
3 min
Video
2026-06-30
Video
3 min
Early-stage venture: Innovation versus hype
Wellington Access Ventures' Jackson Cummings discusses promising innovations in edge AI and embedded fintech. In addition, he highlights the potential hype surrounding consumer AI and quantum computing.
3 min
Video
2026-06-30
Article
8 min
Sizing private-market allocations
Our multi-asset experts explore three key components of sizing private market allocations, offering a framework to evaluate the capacity to take on illiquidity, the need for excess return, and the ability to consistently source 'good' investments.
8 min
Article
2026-05-31
Whitepaper
12 min
When will capital come back to private equity?
Head of Multi-Asset Strategy Adam Berger and Head of Late-Stage Growth Matt Witheiler consider the state of the private equity market, including liquidity challenges, the effects of higher interest rates, late-stage opportunities, and the impact of AI.
12 min
Whitepaper
2026-03-31
Video
2 min
Climate venture capital: Deployment, valuations, exits
Greg Wasserman, head of private climate investing, explores today’s normalizing valuations, encouraging IPO and M&A trends, and potentially actionable opportunities in climate venture capital.
2 min
Video
2026-03-31
URL References
Related Insights